|
India News Briefs
IDC sees VPN boom by 2006
Virtual private network (VPN) services are likely to gross revenues
of
Rs 858 crore in 2006, up from Rs 98.05 crore in 2001, resulting
in a CAGR of 63 percent, according to a latest IDC-India report
on VPN. “The growth in 2002 (Rs 225 crore) over 2001 was exceptionally
high at 13 percent due to a relatively lower base,” said Shekhar
Avasthy, who heads IDC’s Internet, Communications and Convergence
research division. Many network managers in Asia Pacific are considering
IPVPNs (Internet protocol VPNs) as enhancements to, or even replacements
for, conventional frame relay or ATM WAN services, the report said.
Working capital of tech firms up in 2001-02
Working capital represents the excess of current assets over current
liabilities. The total working capital of 29 major IT companies,
which have annual sales over Rs 80 crore, increased by 4.20 percent
to Rs 14,516 crore during 2001-02 from Rs 13,932 crore during 2000-01.
Of the 29 IT companies selected by Financial Express’ Research
Bureau for this study, 31 percent were found to have reduced their
financial strength measured in terms of working capital in 2001-02
over the previous year. The present study traces the trend of working
capital per rupee of sales and profit ration for 29 IT companies
in 2001-02 and 2000-01. Data for the 29 IT companies have been computed
from individual balance sheets.
TCS to roll out bioinfo database appliance
soon
India’s largest software firm, Tata Consultancy Services (TCS),
is all set to enter into the bioinformatics market with its indigenously
developed computing platforms and applications within this year.
The company, which has already invested around Rs 10 crore to nurture
its 40-member team working exclusively on developing bioinformatics
software solutions, is expected to launch its first database appliance
specifically made for bioinformatics applications before the end
of this year. Moreover, the company is now planning to develop bioinformatics
software applications in collaboration with biotech and pharma companies.
— Financial Express
|
